Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NSD2 | O96028 | 2/20 | 0.54 |
| ▸ | MMP14 | P50281 | 2/20 | 0.54 |
| ▸ | CASP6 | P55212 | 2/20 | 0.54 |
| ▸ | EGFR | P00533 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 5/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2433663 | 1.00 | NSD2 (0.54) | NSD2MMP14CASP6EGFRMAPT | |
| SCHEMBL11653798 | 0.88 | NSD2 (0.58) | NSD2MMP14CASP6EGFRMAPT | |
| SCHEMBL11653804 | 0.88 | NSD2 (0.58) | NSD2MMP14CASP6EGFRMAPT | |
| SCHEMBL29635269 | 0.86 | EGFR (0.49) | NSD2MMP14CASP6EGFRMAPT | |
| SCHEMBL2440067 | 0.86 | EGFR (0.49) | NSD2MMP14CASP6EGFRMAPT | |
| SCHEMBL2440064 | 0.86 | EGFR (0.49) | NSD2MMP14CASP6EGFRMAPT | |
| SCHEMBL112102 | 0.84 | EGFR (0.69) | NSD2MMP14CASP6EGFRMAPT | |
| SCHEMBL29378452 | 0.84 | EGFR (0.69) | NSD2MMP14CASP6EGFRMAPT | |
| SCHEMBL112101 | 0.84 | EGFR (0.69) | NSD2MMP14CASP6EGFRMAPT | |
| SCHEMBL10894513 | 0.83 | KDM4E (0.55) | MAPTALDH1A1MEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2368558-A1 | Azo compounds reducing formation and toxicity of amyloid beta aggregation intermediates | Mdc Max-Delbrück-Centrum Für Molekulare Medizin Berlin - Buch (DE) | 2011-09-28 | — | — | EP | claimed |
| JP-5017766-A | — | — | None | — | — | JP | disclosed |
| US-8974768-B2 | Azo compounds reducing formation and toxicity of amyloid beta aggregation intermediates | MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN (DE) | 2015-03-10 | — | — | US | disclosed |
| US-20130078186-A1 | AZO COMPOUNDS REDUCING FORMATION AND TOXICITY OF AMYLOID BETA AGGREGATION INTERMEDIATES | MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN (DE) | 2013-03-28 | — | — | US | disclosed |
| EP-2549999-A1 | AZO COMPOUNDS REDUCING FORMATION AND TOXICITY OF AMYLOID BETA AGGREGATION INTERMEDIATES | Max-Delbrück-Centrum für Molekulare Medizin (DE) | 2013-01-30 | — | — | EP | disclosed |
| WO-2011117305-A1 | AZO COMPOUNDS REDUCING FORMATION AND TOXICITY OF AMYLOID BETA AGGREGATION INTERMEDIATES | Max-Delbrück-Centrum für Molekulare Medizin (DE) | 2011-09-29 | — | — | WO | disclosed |
| EP-2368558-A1 | Azo compounds reducing formation and toxicity of amyloid beta aggregation intermediates | Mdc Max-Delbrück-Centrum Für Molekulare Medizin Berlin - Buch (DE) | 2011-09-28 | — | — | EP | disclosed |
| JP-H0517766-A | ELECTRICAL FIELD LUMINOUS ELEMENT | RICOH CO LTD | 1993-01-26 | — | — | JP | disclosed |
| US-4137228-A | HIGH TINCTORIAL STRENGTH, COLORFASTNESS | CASSELLA AKTIENGESELLSCHAFT (DE) | 1979-01-30 | — | — | US | disclosed |
| US-3966703-A | Asymmetrical frisazo dyestuffs derived from diazotized 2,7-diamino-carbazole | BAYER AKTIENGESELLSCHAFT (DT) | 1976-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130078186-A1 | AZO COMPOUNDS REDUCING FORMATION AND TOXICITY OF AMYLOID BETA AGGREGATION INTERMEDIATES | APP, TTR, CRYAB | NSD2 4178/4885MMP14 3764/4885CASP6 1102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.